Hartford, CTNCT07221253Now EnrollingIRB Ready

Biliary Tract Cancer Clinical Trial in Hartford, CT

Access cutting-edge biliary tract cancer treatment through this clinical trial at a research site in Hartford. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Hartford location

Preparing your pre-screening questions…

Expert Care in Hartford

Access biliary tract cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related biliary tract cancer treatment provided free

Apply for This Hartford Location

Check if you qualify for this biliary tract cancer clinical trial in Hartford, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Hartford

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Hartford site if eligible
  4. 4Begin participation

About This Biliary Tract Cancer Study in Hartford

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Histologically confirmed adenocarcinoma of the biliary tract, including intra-hepatic or extra-hepatic cholangiocarcinoma (CCA) and gallbladder carcinoma (GBC).
Unresectable locally advanced or metastatic BTC, previously untreated in the advanced disease setting
Known PD-L1 status assessed at a central laboratory using an acceptable tumor sample.
Measurable disease by RECIST 1.1 criteria using CT or MRI and is suitable for accurate repeated measurements.
ECOG Performance Status of 0 or 1 with no deterioration (ie, ECOG PS \> 1) over the previous 2 weeks prior to baseline at screening and prior to randomization.
Adequate bone marrow and organ function. Key

Exclusion Criteria

Ampullary carcinoma
Any prior systemic therapy received for unresectable, locally advanced or metastatic BTC.
Any prior exposure to any other therapy targeting immune-regulatory receptors or mechanisms.
Any concurrent chemotherapy, radiotherapy, immunotherapy, investigational, biologic, or hormonal therapy for cancer treatment other than those under investigation in this study.
Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
Active or ongoing interstitial lung disease/pneumonitis (of any grade), serious chronic gastrointestinal conditions associated with diarrhea, or active non-infectious skin disease (including any grade rash, urticaria, dermatitis, ulceration, or psoriasis) requiring systemic treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Hartford?

Yes, this clinical trial (NCT07221253) has an active research site in Hartford, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Biliary Tract Cancer Treatment Options in Hartford, CT

If you're searching for biliary tract cancer treatment options in Hartford, CT, this clinical trial (NCT07221253) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Hartford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced biliary tract cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all biliary tract cancer clinical trials near you to find additional studies recruiting in your area.

More Gallbladder Cancer Trials in Hartford, CT

See all gallbladder cancer clinical trials recruiting in Hartford — not just this study.

Browse Gallbladder Cancer Trials in Hartford →

Browse More Trials by Condition

Gallbladder Cancer TrialsRheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Hartford?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Hartford, CT